Ipamorelin

Ipamorelin is a synthetic pentapeptide ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR-1a) and tells the pituitary to release GH. Selectivity is its calling card. Where GHRP-2 and GHRP-6 drag cortisol and ACTH up alongside GH, ipamorelin — in animal studies — lifts GH without significantly moving ACTH or cortisol beyond what GHRH itself does. It also barely touches appetite compared to MK-677, a difference that comes down to how it sits on the receptor. In animal work it usually shares the syringe with a GHRH analog like CJC-1295, the idea being that hitting the GHRH receptor and the GHSR at once amplifies the GH pulse more than either alone.

The ipamorelin evidence base is almost entirely preclinical, and that is not a hedge — it is the fact. Raun et al. (1998, Eur J Endocrinol) first characterized it in pig and rat models, pinning down its receptor selectivity and GH-releasing potency. Later animal work chased its gut effects: Venkova et al. (2009, J Pharmacol Exp Ther) showed it sped gastric motility in a rodent model of postoperative ileus. What is missing is the part that counts for a human buyer — there are no published human RCTs, and no large observational studies, of ipamorelin on its own. And the ipamorelin + CJC-1295 protocol traded around sports and biohacking forums? No clinical trial data in humans backs it.

• Selective GH release without significant ACTH or cortisol elevation in rat and pig models (Raun et al. 1998)
• Faster gastric emptying in a rodent postoperative ileus model (Venkova 2009)
• Bigger GH pulses in animals when paired with a GHRH analog

• No published human RCTs — all evidence is preclinical; human efficacy and safety are unestablished
• Sold for research use only; purity and dosing accuracy depend entirely on the supplier
• Unknown long-term effects in humans
• The selective profile demonstrated in animals may not translate to humans
• Banned in sport by WADA

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: GH / IGF-1 support, Body composition

Is ipamorelin safer than other GHRPs?

In animal models, ipamorelin shows better selectivity for GH release: the characterization study (Raun et al., 1998) found ACTH and cortisol levels not significantly different from GHRH controls, unlike older GHRPs. Whether this selectivity advantage translates to a meaningfully different safety profile in humans is unknown — there are no human comparative trials.

Why is ipamorelin always discussed with CJC-1295?

The combination targets two different pathways: ipamorelin binds the GHSR (ghrelin receptor) and CJC-1295 binds the GHRH receptor. In animals, this synergy amplifies GH pulses more than either compound alone. The combination is popular online, but has no published human clinical trial data.

Does ipamorelin suppress natural GH production?

There is no human data to definitively answer this. In animal models it works within the normal pituitary feedback system and does not appear to suppress endogenous GHRH, but long-term suppression effects in humans are unknown.

1. [1]
   Ipamorelin, the first selective growth hormone secretagogue

   Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · European Journal of Endocrinology · 1998 · PMID 9849822 · model: animal

   Original characterization of ipamorelin in pig and rat models, establishing its potent and selective stimulation of GH release without significant ACTH or cortisol elevation — the key selectivity finding that distinguishes it from older GHRPs.

2. [2]
   Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

   Venkova K, Fraser G, Hoveyda HR, Greenwood-Van Meerveld B · The Journal of Pharmacology and Experimental Therapeutics · 2009 · PMID 19289567 · model: animal

   Ipamorelin accelerated gastric emptying and restored GI motility in a rat model of postoperative ileus, pointing to potential GI applications beyond GH stimulation — though not yet tested in humans.